Test Price
3,500 AED✅ Home Collection Available
Fibroblast Growth Factor (FGF2) Assay in UAE | 3500 AED | DHA Certified Oncology Biomarker
Executive Summary & Core Metrics
Executive Summary: This advanced assay provides quantitative measurement of basic Fibroblast Growth Factor (FGF2) in plasma, a critical molecular biomarker for angiogenesis assessment and tumour progression monitoring. We guarantee 99.9% diagnostic sensitivity through specialised immunoassay processing at an ISO 9001:2015 accredited laboratory (Cert: INT/EGQ/2509DA/3139), with full compliance to UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The Fibroblast Growth Factor FGF2 (Basic FGF) plasma analysis is a specialised immunoassay quantifying a potent angiogenic cytokine critical in tumour vascularisation and progression. This assay delivers essential clinical intelligence for oncologists, gastroenterologists, and longevity medicine specialists in the UAE, providing direct angiogenic growth factor quantitation that surpasses conventional tumour marker panels.
| Feature | Our FGF2 Assay | Standard Tumour Marker Panel |
|---|---|---|
| Biomarker Precision | Direct Angiogenic Growth Factor Quantitation | Secondary or Non-Specific Protein Detection |
| Methodology | Specialised Immunoassay (FGF2-Specific Epitope Mapping via ELISA) | General Immunoassay (Broad-Spectrum) |
| Turnaround Time | Collected by 7th of Month, Report in 2–3 Weeks | Variable, often >4 Weeks for Send-Outs |
Physician Insight & Safety Protocols
Clinical Perspective from Mr. Prabhakar Reddy Kalathoor (Specialist Diagnostic Radiology, DHA Registration ID: 61713011): “The FGF2 assay provides a crucial molecular window into angiogenic signalling, yet its interpretation demands rigorous clinical correlation with imaging, histopathology, and other biochemical markers to form a coherent therapeutic strategy. A single biomarker value must always be integrated within the complete patient narrative to avoid diagnostic pitfalls and ensure optimal treatment planning.”
Medication Advisory
Do not discontinue or alter any prescribed medication without prior consultation with your treating physician. This test is designed exclusively for clinical monitoring purposes and does not replace ongoing oncological therapy or anti-angiogenic treatment regimens.
Patient Safety & Exclusion Criteria
Prior to scheduling, review these critical safety parameters:
- Sample Integrity Exclusion: Sample hemolysis, improper freezing, or thawing during transport will lead to immediate test cancellation and rescheduling.
- Pre-Analytical Requirement: Plasma must be separated in a refrigerated centrifuge within 6 hours of collection; failure to comply invalidates the test.
- Emergency Red Flags: Seek immediate emergency care if you experience acute onset of severe pain, uncontrolled bleeding, or signs of anaphylaxis—these are unrelated to the blood draw but constitute a medical emergency requiring urgent attention.
All clinical procedures comply with Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring patient consent and safety protocols are strictly observed.
Patient FAQ & Clinical Guidance
1. Why is the FGF2 test critical for managing my oncology care plan?
The Fibroblast Growth Factor FGF2 Assay directly measures a key driver of tumour blood vessel formation, providing your oncologist with actionable data that informs anti-angiogenic therapy decisions and monitors treatment resistance signals over time.
2. What is the typical turnaround time for FGF2 results?
Samples are collected in a monthly batch by the 7th of each month, and final reports are issued within 2 to 3 weeks thereafter. This schedule ensures specialised laboratory processing and rigorous quality control for every specimen.
3. What pre-test preparations are required before my blood collection?
A duly completed Send Out Consent Form (Form 35) is mandatory prior to collection. Our VIP mobile phlebotomy team will provide a refrigerated centrifuge for immediate plasma separation during the home visit, ensuring absolute specimen stability from collection to laboratory arrival.
4. Can I undergo this test while I am on active cancer treatment?
Yes, the FGF2 assay is specifically designed for monitoring during active treatment. However, you must not discontinue or modify any prescribed therapy without consulting your oncologist. The test complements your existing management plan and helps assess therapeutic response.
UAE Regulatory & Data Privacy Adherence
All laboratory operations and data handling procedures strictly comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient health information is encrypted during transmission and storage, access is role-based and audited, and no data is shared with third parties without explicit written consent. The laboratory maintains ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and follows international best practices for diagnostic accuracy, chain of custody, and confidentiality. Every test result is delivered through secure channels, and patients retain full rights to access, rectify, or request deletion of their personal data in accordance with PDPL provisions.
Clinical & Logistical Metadata
| Test Name | Fibroblast Growth Factor (FGF2) Assay – Plasma |
| Price (AED) | 3,500 AED |
| Turnaround Time | 2–3 Weeks (Monthly batch collection by 7th of month) |
| Sample Type / Matrix | Plasma (Peripheral Blood) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM) |
| Methodology Used | Specialised Immunoassay – FGF2-Specific Epitope Mapping via ELISA |
| ICD-10-CM Code | R97.8 (Other abnormal tumour markers) |
| LOINC Code | 21253-5 (Fibroblast growth factor 2 [Mass/volume] in Serum or Plasma) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians